Crystal Lake, Illinois, February 5, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today reported the following fourth quarter results for the period ended December 31, 2025, as compared to the corresponding period of the last fiscal year.
Fourth Quarter 2025 Highlights
(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)
- Reported sales increased 14% and core sales increased 5%—all three segments delivered core sales growth
- Reported net income decreased 26% to $74 million and reported earnings per share decreased 24% to $1.13
- Adjusted earnings per share were $1.25
- Adjusted EBITDA margin was 8% compared to 23.0% in the prior year
- Returned $206 million to shareholders through share repurchases and dividends
- Subsequent to the quarter, the Board of Directors has approved a new authorization for the repurchase of up to $600 million of the Company’s common stock
Annual 2025 Highlights
(Compared to the prior year period; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)
- Reported sales increased 5% and core sales increased 2%
- Reported net income increased 5% to $393 million and reported earnings per share increased 7% to $5.89
- Returned $486 million to shareholders through share repurchases and dividends
- Capital expenditures decreased year over year, ending the year at about 7% of sales
- 2025 was our 32nd consecutive year of paying an annually increasing dividend
“All three segments delivered core sales growth, driving a total increase of 5% in the fourth quarter and underscoring our strong market positions and the benefits of our innovation‑led portfolio. Our Pharma segment’s growth was driven by strong demand for our elastomeric components, continued demand for our systemic nasal drug delivery technologies and the return to growth for our consumer healthcare division. Our Beauty segment delivered double-digit growth, driven by healthy demand for our dispensing technologies across all end markets, and our Closures segment had strong product volume growth. A combination of product mix and some higher than expected production costs reduced the impact of our strong top line results on our overall profitability in the quarter. We remain confident in our ability to drive performance and to continue creating value for shareholders,” said Stephan B. Tanda, Aptar President and CEO.
Download the full press release here.
